Epstein Files Search

Dataset

Sort

Status

DOJ Status

Date Range

–

Page Count

–

Corpus: 1990-03-17 – 2025-12-01

January 2014

None

Light

Medium

Heavy

Results by Dataset119 total

Set 8

Set 9

Set 10

Set 11

results for “"Novartis"”

Keyboard Shortcuts

/

Focus search

Esc

Blur input

O

Open PDF

←→

Paginate

EFTA00633452Set 9

2014-01-073p872w

WIRE)-- Foundation Medicine today announced it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis ... extend through at least September 2016. As the result of Foundation Medicine and Novartis' pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation ... profiling has generated clinically relevant data and is now regularly used in many of Novartis' oncology clinical trials. This new agreement, which the companies agreed to extend and expand prior

https://www.justice.gov/epstein/files/DataSet%209/EFTA00633452.pdf

EFTA00370849Set 9

2014-04-226p1,752w

make a run at Allergan (AGN +21% after the close). And now Novartis & GSK have announced a major series of transactions: creating new consumer-health venture (GSK 63.5% controlling interest ... Novartis agrees to buy GSK's oncology unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit ... premium) • Novartis/GSK major 3-part transaction, exchange certain assets, form consumer-health venture • Novartis to divest Animal Health to Lilly for $5.4B (NOVN

https://www.justice.gov/epstein/files/DataSet%209/EFTA00370849.pdf

EFTA01565500Set 10

2013-04-0147p4,657w

GESELLSCHAFT ADR MURG Y NESTLE S A SPONS ADR REPSTG REG SH NSRG Y NOVARTIS A G ADR NVS PETROCHINA CO LTD ADR PTR PROCEEDS FROM PENDING SALES RECKITT BENCKISER ... 03/01/13 - 03/31/13 @ .01% RATE ON AVG COLLECTED BALANCE OF $25,583.73 AS OF 04/01/13 NOVARTIS A G ADR @ 2.42647 PER SHARE (ID: ) GLAXOSMITHKLINE PLC SPONS ADR @ 0.68948 PER SHARE ... 4/11 4/12 4/22 Expenses Expenses Expenses Expenses Total Withdrawals Fees & Commissions 4/18 4/18 Description NOVARTIS A G ADR .005 DSC FEE FOR 04/05/2013 PAYMEN T AS OF 04/05/13 (ID: ) ROCHE

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01565500.pdf

EFTA01565547Set 10

2013-04-01157p15,782w

NESTLE S A SPONS ADR REPSTG REG SH 641069-40-6 NSRG Y NOVARTIS A G ADR 66987V-10-9 NVS PETROCHINA CO LTD ADR 71646E-10-0 PTR PROCEEDS FROM ... 03/01/13 - 03/31/13 @ .01% RATE ON AVG COLLECTED BALANCE OF $25,583.73 AS OF 04/01/13 NOVARTIS A G ADR @ 2.42647 PER SHARE (ID: 66987V-10-9) NOVARTIS ... WITHHELD SWITZERLAND 15.00% (ID: 66987V-10-9) NOVARTIS A G ADR .005 DSC FEE FOR 04/05/2013 PAYMEN T AS OF 04/05/13 (ID: 66987V-10-9) GLAXOSMITHKLINE PLC SPONS

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01565547.pdf

EFTA00814568Set 9

2018-05-093p553w

came after a lawyer for porn star Stormy Daniels claimed the company, drug giant Novartis and a Russian oligarch had all made payments to Cohen's shell company. Daniels' lawyer ... deal. In a report on Cohen's company, Avenatti's law firm said that Novartis in late 2017 and early 2018 made four separate payments to Essential Consultants totaling nearly ... payments, reports surfaced that Mr. Trump took a dinner with the incoming CEO of Novartis before Mr. Trump's speech at the World Economic Forum in Davos, Switzerland in late

https://www.justice.gov/epstein/files/DataSet%209/EFTA00814568.pdf

EFTA01274387Set 10

2014-02-02330p153,621w

Current yield: 2.58% 2210.000 --This information was unaniable--- 28.240 62,410.40 NOVARTIS AG SPON ADR Symbol: NW Exchange: NYSE EAI: 11,723 Current yield: 2.12% 975.000 --This information was unamiable ... liPPON TELEG & TEL CORP SPON Al:Ft 2210.000 62A98.80 CU9P: 654624105 Feb26 Receive Dtc NOVARTIS AG SPON AOR 975.000 81,324.75 CUSIP: 66987VI 09 Feb26 Receive Dtc LUKOR ... Security total 2210.000 26.414 5837487 60200.40 1,825.53 NOVARTIS AG SPON ADR Symbol: NV5 Exchange: NYSE EAI: 41,723 Current yield

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01274387.pdf

EFTA01113739Set 9

37p2,922w

Decreases the tissue formation of endogen histamine from histidine ■ Marketed internationally since 1960 (Chiesi — Novartis consumer health) for the treatment of various allergic conditions o 300 to 900mg/d with ... primary tumour tissues/ Phase III in renal cell carcinoma-phase II in colon cancer • Novartis -Transgene Option : 995M$ deal in 2010 Muc tumor antigen/ IL2 recombinant Virus in Phase ... NSCLC/ first line Treatment Deal with Novartis 10M$ upfront in phase Ilb /III • AB Sciences (594M€ Euronext) Masitinib at registration stage in Pancreatic cancer + other indications OSE Pra is EFTA01113772

https://www.justice.gov/epstein/files/DataSet%209/EFTA01113739.pdf

EFTA00032951Set 8

2020-07-145p1,965w

York City Bar Association Panama Papers Attys Fight Netflix Bid To Nix Defamation Suit Novartis AG The attorneys whose now-defunct firm Mossack Fonseca was involved in the Panama Papers ... ANALYSIS U.S. District Court for the Central District of California 5 Compliance Lessons From Novartis' FCPA Settlement U.S. District Court for the District of Novartis' parallel settlements with

https://www.justice.gov/epstein/files/DataSet%208/EFTA00032951.pdf

EFTA00032942Set 8

2020-02-135p2,143w

equate to fraud. Read full article » New York University Nissan Motor Co. Ltd. TAX Novartis AG PNC Financial Services Group Inc. Export Business Owner Gets 3 Years For Concealing Income ... attorneys work. U.S. District Court for the Northern Read full article » District of Illinois Novartis Taps Firms Ready To Pony Up On Diversity — Or Else U.S. District Court ... Southern Novartis AG on Wednesday said it has chosen nearly two dozen preferred District of New York law firms that have agreed to diverse staffing requirements for each legal

https://www.justice.gov/epstein/files/DataSet%208/EFTA00032942.pdf

EFTA01518423Set 10

2013-04-011p255w

RATE ON AVG COLLECTED BALANCE OF $25,583.73 AS OF 04/01/13 4/5 Foreign Dividend NOVARTIS A G ADR 2.42647 PER SHARE 590.000 2.426 1,431.62 (ID: 66967V ... Withheld NOVARTIS A G ADR TAX WITHHELD SWITZERLAND 590.000 (214.74) 15.00% (ID: 66967V-10-9) 4/9 Expenses NOVARTIS A G ADR .005 DSC FEE FOR 04/05/2013 590 000 (2.95) PAYMEN

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01518423.pdf

EFTA00642436Set 9

2013-04-2121p13,686w

sell its products to another manufacturer. Apotex, a Canadian company, said the drug maker Novartis denied it access to Tasigna, a leukemia drug, until Apotex threatened to sue. Another company ... treats a movement disorder caused by Huntington's disease. Julie Masow, a spokeswoman for Novartis, said Apotex ultimately purchased samples of Tasigna through the drug's sole distributor. She said ... delay was the result of a misunderstanding, adding "generic companies arefree to buy Novartis products through distribution channels." Representatives of brand-name manufacturers say there are good reasons to restrict

https://www.justice.gov/epstein/files/DataSet%209/EFTA00642436.pdf

EFTA00032976Set 8

2018-08-315p2,152w

full article » Altman Weil Inc. CONTRACTS Amgen Inc. DOJ Says It Can Prove Novartis Dinners Were Kickbacks Archrock Inc. The U.S. Department of Justice shot back against Novartis Pharmaceuticals ... Association way for the purchase of the Houston Rockets, opening the door for major Novartis AG retailers like Walmart Inc. to sell liquor in Texas and reshaping oilfield ownership. Read

https://www.justice.gov/epstein/files/DataSet%208/EFTA00032976.pdf

EFTA02390836Set 11

2012-02-153p422w

Investor Daily <613964.1230007213@ems.euromoneyplc.com> Sent: Wednesday, February 15, 2012 3:53 PM To: jeeproject@yahoo.com Subject: Novartis CEO Joseph Jimenez Pushes Drug Discovery <http://projectsline.com/iimag/images=x.gif> <http://ems.euromoney.com/ems/r.asp?clndex=613964&=Index=1230007213&hurl=http%3A//www.institution alinvestor.com> =!-- Newsletter Title ... 18px; TEXT-DECORATION: none; PADDING-TOP: 0px" href="http://ems.=uromoney.com/ems/r.asp?clndex=613964&mlndex=1230007213&hurl=htt=%3A//www.institutionali nvestor.com/Article/2977587/Novartis-CEO-Joseph-=imenez-Pushes-Drug-Discovery.html">Novartis CEO Joseph Jimenez Pushes D=ug Discovery Joseph Jimenez thrives=on competition. As a teenager ... pharmaceuticals giant Novartis s=ent four hours a day, seven days a week, practicing for swim meets...=/P>Read the full story at institutio=alinvestor.com. <http://ems=2Eeuromoney.com/ems/r.asp?clndex=613964&mlndex=1230007213&hurl==ttp%3A//www.institutionalin vestor.com

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02390836.pdf

EFTA01274717Set 10

2015-10-02224p112,706w

Security total 2.210.000 26.414 58,374.87 81,173.30 22,79843 NOVARTIS AG SPON ADR Symbol: NVS Exchange: NYSE EAI: 52.203 Current yield

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01274717.pdf

EFTA01103797Set 9

2013-09-2315p5,239w

Investment Fund Governance Investment Committee ■ William Greene, MPM Capital, MD Venture Partner ■ Andrin Oswald, Novartis, Division Head — Novartis Vaccines and Diagnostics ■ George Wellde, Goldman Sachs, Vice Chairman of Securities Division

https://www.justice.gov/epstein/files/DataSet%209/EFTA01103797.pdf

EFTA00397162Set 9

2013-01-237p2,279w

announcement and guiding touch lower). Healthcare +1.28% & Food/Beverages +0.72% also outperforming in Europe as Novartis +3.8% & Unilever +2.4% break-out after reporting solid numbers. Volumes heavy across the region with ... Billiton production numbers in line, Escondida ahead, maintaining guidance & cost savings (trading +0.85%) • Novartis good O4, Bayer's Reinhardt replaces Vasella as chairman, light guidance of fiat 2013 (trading

https://www.justice.gov/epstein/files/DataSet%209/EFTA00397162.pdf

EFTA01564970Set 10

2013-01-0134p3,114w

MURG NESTLE S A SPONS ADR REPSTG REG SH 641069-40-6 NSRG NOVARTIS A G ADR 66987V-10-9 NVS PETROCHINA CO LTD ADR 71646E-10-0 PTR RECKITT BENCKISER ... NESTLE S A SPONS ADR REPSTG REG SH (ID: 641069-40-6) EFTA01564994 NOVARTIS A G ADR (ID: 66987V-10-9) LUKOIL OAO SPONS ADR (ID: 677862-10-4) TELEKOMUNIKASI

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01564970.pdf

EFTA01566101Set 10

2013-07-01167p16,599w

NSRG Y NIPPON TEL & TEL CORP ADR 654624-10-5 NTT NOVARTIS A G ADR 66987V-10-9 NVS P PETROCHINA CO LTD ADR 71646E-10-0 PTR PROCEEDS FROM PENDING ... BROKERAGE 7.80 ESI SECURITIES COMPANY (ID: 641069-40-6) NOVARTIS A G ADR @ 73.4109 10,644.58 BROKERAGE 5.80 ESI SECURITIES COMPANY (ID: 66987V-10-9) LUKOIL OAO SPONS

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01566101.pdf

EFTA01457559Set 10

2016-05-111p416w

consensus of 23.6%). This deterioration reflects pricing pressure on Advair and impact of the Novartis transaction. Management is now guiding to a c.500bp drag on margins for the FY partly ... result of greater than expected costs from the acquired vaccines division of Novartis. Core EPS of 17.3p (-16% CER) was 2% below consensus. investor Event Credible plans

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01457559.pdf

EFTA02686169Set 11

2011-01-1828p14,325w

Richard P. Eno Chief Executive Officer Metabolix USA David R. Epstein Head. Pharma Division Novartis AG Switzerland Mary Callahan Erdoes Chief Executive Officer, Asset JPMorgan Chase & Co. USA Management Charles

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02686169.pdf